NCT02240433 2020-02-05
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
3 trialsNCT02734160 2019-08-05
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02154646 2016-02-10
A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body
Eli Lilly and Company
Phase 1 Completed